378 related articles for article (PubMed ID: 34834468)
21. New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer's Disease.
Penke B; Szűcs M; Bogár F
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982456
[TBL] [Abstract][Full Text] [Related]
22. Milrinone Ameliorates the Neuroinflammation and Memory Function of Alzheimer's Disease in an APP/PS1 Mouse Model.
Chen Q; Yin Y; Li L; Zhang Y; He W; Shi Y
Neuropsychiatr Dis Treat; 2021; 17():2129-2139. PubMed ID: 34234439
[TBL] [Abstract][Full Text] [Related]
23. NLRP1 Inflammasome Activation in the Hippocampal Formation in Alzheimer's Disease: Correlation with Neuropathological Changes and Unbiasedly Estimated Neuronal Loss.
Španić E; Langer Horvat L; Ilić K; Hof PR; Šimić G
Cells; 2022 Jul; 11(14):. PubMed ID: 35883667
[TBL] [Abstract][Full Text] [Related]
24. Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms.
Iliyasu MO; Musa SA; Oladele SB; Iliya AI
Front Neurosci; 2023; 17():1081938. PubMed ID: 37113145
[TBL] [Abstract][Full Text] [Related]
25. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's Disease and Protein Kinases.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():285-321. PubMed ID: 33539020
[TBL] [Abstract][Full Text] [Related]
27. Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation.
Chen Y; Yu Y
J Neuroinflammation; 2023 Jul; 20(1):165. PubMed ID: 37452321
[TBL] [Abstract][Full Text] [Related]
28. Peony seed oil ameliorates neuroinflammation-mediated cognitive deficits by suppressing microglial activation through inhibition of NF-κB pathway in presenilin 1/2 conditional double knockout mice.
Gao J; Wang L; Zhao C; Wu Y; Lu Z; Gu Y; Ba Z; Wang X; Wang J; Xu Y
J Leukoc Biol; 2021 Dec; 110(6):1005-1022. PubMed ID: 34494312
[TBL] [Abstract][Full Text] [Related]
29. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
30. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
Kazim SF; Iqbal K
Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
[TBL] [Abstract][Full Text] [Related]
31. Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota.
Qu C; Li QP; Su ZR; Ip SP; Yuan QJ; Xie YL; Xu QQ; Yang W; Huang YF; Xian YF; Lin ZX
J Adv Res; 2022 Jan; 35():231-243. PubMed ID: 35024199
[TBL] [Abstract][Full Text] [Related]
32. Role of NLRP3 Inflammasome and Its Inhibitors as Emerging Therapeutic Drug Candidate for Alzheimer's Disease: a Review of Mechanism of Activation, Regulation, and Inhibition.
Sharma B; Satija G; Madan A; Garg M; Alam MM; Shaquiquzzaman M; Khanna S; Tiwari P; Parvez S; Iqubal A; Haque SE; Khan MA
Inflammation; 2023 Feb; 46(1):56-87. PubMed ID: 36006570
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in the Modeling of Alzheimer's Disease.
Sasaguri H; Hashimoto S; Watamura N; Sato K; Takamura R; Nagata K; Tsubuki S; Ohshima T; Yoshiki A; Sato K; Kumita W; Sasaki E; Kitazume S; Nilsson P; Winblad B; Saito T; Iwata N; Saido TC
Front Neurosci; 2022; 16():807473. PubMed ID: 35431779
[TBL] [Abstract][Full Text] [Related]
34. CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer's Disease.
Bivona G; Iemmolo M; Ghersi G
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175935
[TBL] [Abstract][Full Text] [Related]
35. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.
Kang BW; Kim F; Cho JY; Kim S; Rhee J; Choung JJ
Alzheimers Res Ther; 2022 Jul; 14(1):92. PubMed ID: 35804462
[TBL] [Abstract][Full Text] [Related]
36. GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update.
Chauhan N; Paliwal S; Jain S; Verma K; Paliwal S; Sharma S
Mini Rev Med Chem; 2022; 22(22):2881-2895. PubMed ID: 35450523
[TBL] [Abstract][Full Text] [Related]
37. Miltefosine as a PPM1A activator improves AD-like pathology in mice by alleviating tauopathy via microglia/neurons crosstalk.
Lv J; Shen X; Shen X; Li X; Jin Z; Ouyang X; Lu J; Zhu D; Wang J; Shen X
Brain Behav Immun Health; 2022 Dec; 26():100546. PubMed ID: 36388134
[TBL] [Abstract][Full Text] [Related]
38. p110δ PI3-Kinase Inhibition Perturbs APP and TNFα Trafficking, Reduces Plaque Burden, Dampens Neuroinflammation, and Prevents Cognitive Decline in an Alzheimer's Disease Mouse Model.
Martínez-Mármol R; Mohannak N; Qian L; Wang T; Gormal RS; Ruitenberg MJ; Vanhaesebroeck B; Coulson EJ; Meunier FA
J Neurosci; 2019 Oct; 39(40):7976-7991. PubMed ID: 31363064
[TBL] [Abstract][Full Text] [Related]
39. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
40. Non-Coding RNA in Microglia Activation and Neuroinflammation in Alzheimer's Disease.
He C; Li Z; Yang M; Yu W; Luo R; Zhou J; He J; Chen Q; Song Z; Cheng S
J Inflamm Res; 2023; 16():4165-4211. PubMed ID: 37753266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
